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neered to express p210 BCR-ABL ( Figure 1a ). The incidence of apoptosis was determined by flow cytometric analysis with an FITCconjugated APO2.7 monoclonal antibody (clone 2.7), which was raised against the 38 kDa mitochondrial membrane protein (7A6 antigen) expressed by cells undergoing apoptosis. 7 Incubation with up to 10 M STI571 for 48 h did not result in increased apoptosis among parental TF-1 cells in the presence of GM-CSF (100 U/ml). Further, even though the incubation of TF-1 BCR-ABL cells with STI571 at a concentration of either 1 M or 10 M induced apoptosis in the absence of GM-CSF, the addition of GM-CSF abated the apoptotic effects of STI571 in these cells ( Figure 1b) .
Next, we examined the induction of apoptosis in primary leukemic blasts from 10 patients with acute leukemia (Figure 1c ) (Table 1 ). All patients provided informed consent prior to conducting studies. Leukemic blasts were isolated from bone marrow of four patients with Ph-positive ALL (p185 BCR-ABL) (from cases 1, 2, 3 and 4), two patients with Ph-negative ALL (cases 5 and 6) and four patients with CML-myeloid BC (p210 BCR-ABL) (from cases 7, 8, 9 and 10) ( Table  1) . Blast cells were incubated in suspension cultures in the presence of 1 or 10 M of STI571 for 48 h, and the occurrence of apoptosis was examined by flow cytometric analysis with FITC-conjugated APO2.7 monoclonal antibody (Figure 1c) . At a concentration of 1 M, STI571 induced apoptosis at very high frequencies in the blast cells from all patients with Ph-positive ALL, whereas no increased apoptosis against background levels was seen in the blast cells from two patients with Ph-negative ALL even in the presence of 10 M STI571 (Figure 1c and Table 1 ). STI571 also induced apoptosis in blast cells from two of the four patients with CML-myeloid BC (cases 9 and 10), however, primary blast cells from CML-myeloid BC seem to be less sensitive to STI571 ( Figure 1c and Table 1 ). Blast crisis is associated with genetic instability and complex karyotypes leading to the activation of other oncogenes in addition to BCR-ABL, as well as to the inactivation of tumor suppressor genes. It is not known if these additional abnormalities replace the requirement of the leukemic clone on BCR-ABL tyrosine kinase activity for survival in blast crisis, however, our results demonstrate that STI571 exhibits specific activity in Ph-positive ALL
Relationship between methylation of the p15 gene and ectopic expression of the EVI-1 gene in myelodysplastic syndromes (MDS)
TO THE EDITOR Transcription of the p15(INK4B) tumor suppressor gene, which encodes a cyclin-dependent kinase inhibitor, is positively regulated by transforming growth factor-␤ (TGF-␤). We previously reported that the hypermethylation of the p15 gene promoter, which should silence and some cases of CML-BC in vitro. Given the extremely poor prognosis of patients with Ph-positive ALL or CML-BC, the results described herein may provide a basis for attractive therapeutic strategies in treating these diseases.
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First Another molecular abnormality frequently found in MDS is the ectopic expression of the ecotropic virus integration site-1 (EVI-1) gene. The EVI-1 gene was cloned as a gene activated by viral integration in murine leukemia cells, and the human gene was located on the long arm of the chromosome 3 (3q26). The EVI-1 gene is scarcely expressed in normal human hematopoietic cells, but expression was found in some acute myeloblastic leukemia (AML) and MDS, with and without 3q26 abnormalities. 2 Kurokawa et al 3 reported that the EVI-1 protein interacts with SMAD3 protein and blocks the signal from TGF-␤, and in reporter assay overexpression of the EVI-1 protein suppresses transcriptional activation of the p15 gene promoter by TGF- On the other hand, if expression of the EVI-1 gene has other leukemogenic effect(s) in MDS, in addition to suppression of the p15 gene expression, these two abnormalities may more likely be found randomly in MDS cases. These considerations prompted us to examine patients with MDS and acute leukemia evolved from MDS (sAML) for the methylation of the p15 gene and the ectopic expression of the EVI-1 gene. The bone marrow (BM) and peripheral blood (PB) cells from 34 patients (nine RA, two RARS, 10 RAEB, one CMML, seven RAEB-T, five sAML) were examined for the p15 gene by the methylation-specific PCR (MSP) method as previously described, 4 and for the EVI-1 gene by two-step RT-PCR reported by Privitera et al. 5 All samples were obtained with informed consent of the patients. Specific bands amplified with the methylated sequence-specific primer pair (M primers) for the p15 gene were observed in 12 patients, and nested RT-PCR with primers specific for the EVI-1 gene revealed detectable bands in nine patients. Eighteen patients showed at least one of the two abnormalities, and three patients, one with RAEB and two with sAML, showed both alteration. The results are summarized in Table 1 . Table 2 clearly shows that these two events, hypermethylation of the p15 gene and ectopic expression of the EVI-1 gene, are not found in a mutually exclusive way. Statistical analysis with continuity adj. chi-square test confirmed that there is no correlation between the two (P = 0.7750). Thus, methylation of the p15 gene and expression of the EVI-1 gene appear to occur independently in hematologic cells of MDS patients. Tables 1  and 2 .
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We next examined whether there was any correlation between clincal stages and presence or absence of these molecular abnormalities (Table 3) . When distinction between advanced (RAEB, CMML, RAEB-T and sAML) and less advanced (RA and RARS) cases was examined, expression of the EVI-1 gene was not a significant determining factor (P = 0.2408), and methylation of the p15 gene was only of borderline significance (P = 0.0676). The presence of at least one of the two abnormalities, however, was found to be significant (0.0146). This result suggests that the presence of either of the two abnormalities, which was found in about half of our patients, may be a good indicator of disease progression in MDS.
Our results suggest that hypermethylation of the p15 gene and ectopic expression of the EVI-1 gene are important events in disease progression of MDS, and the contribution of the EVI-1 gene may not be restricted to suppression of the p15 gene.
